Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia

References

• Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: a retrospective cohort study. Medicine (Baltimore). 2018;97(39):e12102. doi:10.1097/MD.0000000000012102
   PubMed Web of Science ®Google Scholar
• Masoumi-Dehshiri R, Hashemi AS, Neamatzadeh H, Zare-Zardeini H, Case Report: A. Acute myeloid leukemia (FAB M7). Iran J Ped Hematol Oncol. 2014;4(4):188–190.
   Google Scholar
• Hekmatimoghaddam S, Jebali A, Dargahi M. Folic acid-functionalized gold and silver nanoparticles: their cytotoxic effect on cancerous myeloid cells with microwave irradiation. Nano Life. 2013;3(2):1350003(1–6). doi:10.1142/S1793984413500037
   Google Scholar
• Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011;35(3):301–304. doi:10.1016/j.leukres.2010.09.002
   PubMed Web of Science ®Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(3):17. doi:10.1007/s11864-017-0456-2
   PubMed Web of Science ®Google Scholar
• Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009;109(7):2880–2893. doi:10.1021/cr900028p
   PubMed Web of Science ®Google Scholar
• Harned TM, Gaynon PS. Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag. 2008;4(2):327–336. doi:10.2147/TCRM.S2941
   PubMedGoogle Scholar
• Cooper TM, Alonzo TA, Gerbing RB, et al. AAML0523: a report from the children’s oncology group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014;120(16):2482–2489. doi:10.1002/cncr.28674
   Web of Science ®Google Scholar
• Al-Hussaini M, DiPersio JF. Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic. Expert Rev Hematol. 2014;7(4):439–464. doi:10.1586/17474086.2014.932687
   PubMed Web of Science ®Google Scholar
• Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10(51):1–16. doi:10.1186/s13045-017-0416-0
   Web of Science ®Google Scholar
• Pourrajab F, Zare-Khormizi MR, Hashemi AS, Hekmatimoghaddam S. Genetic characterization and risk stratification of acute myeloid leukemia. Cancer Manag Res. 2020;12:2231–2253. doi:10.2147/CMAR.S242479
   PubMed Web of Science ®Google Scholar
• Wu L, Li X, Su J, et al. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma. 2009;50(9):1461–1467. doi:10.1080/10428190903096719
   PubMed Web of Science ®Google Scholar
• Gavande NS, VanderVere-Carozza PS, Hinshaw HD, et al. DNA repair targeted therapy: the past or future of cancer treatment? Pharmacol Ther. 2016;160:65–83. doi:10.1016/j.pharmthera.2016.02.003
   PubMed Web of Science ®Google Scholar
• Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011;7(2):263–283. doi:10.2217/fon.11.2
   PubMed Web of Science ®Google Scholar
• Mody MD, Gill HS, Higgins KA, Saba NF, Kota VK. Complete remission of acute myeloid leukemia following cisplatin based concurrent therapy with radiation for squamous cell laryngeal cancer. Case Rep Hematol. 2016;2016:8581421.
   Google Scholar
• Laurent G, Jaffrézou JP. Signaling pathways activated by daunorubicin. Blood. 2001;98(4):913–924. doi:10.1182/blood.V98.4.913
   PubMed Web of Science ®Google Scholar
• Lim SH, Dubielecka PM, Raghunathan VM. Molecular targeting in acute myeloid leukemia. J Transl Med. 2017;15(1):183. doi:10.1186/s12967-017-1281-x
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–983. doi:10.1200/JCO.2016.70.7836
   PubMed Web of Science ®Google Scholar
• Zhenchuk A, Lotfi K, Juliusson G, Albertioni F. Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol. 2009;78(11):1351–1359. doi:10.1016/j.bcp.2009.06.094
   Web of Science ®Google Scholar
• Navada SC, Steinmann J, Lübbert M, Silverman LR. Clinical development of demethylating agents in hematology. J Clin Invest. 2014;124(1):40–46. doi:10.1172/JCI69739
   PubMed Web of Science ®Google Scholar
• Braoudaki M, Tzortzatou-Stathopoulou F. Clinical cytogenetics in pediatric acute leukemia: an update. Clin Lymphoma Myeloma Leuk. 2012;12(4):230–237. doi:10.1016/j.clml.2012.04.004
   Web of Science ®Google Scholar
• Magina KN, Pregartner G, Zebisch A, et al. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood. 2017;130(7):946–948. doi:10.1182/blood-2017-04-777722
   PubMed Web of Science ®Google Scholar
• Dervieux T, Brenner TL, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 2002;100(4):1240–1247. doi:10.1182/blood-2002-02-0495
   Web of Science ®Google Scholar
• Zagni C, Floresta G, Monciino G, Rescifina A. The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat. Med Res Rev. 2017;37(6):1373–1428. doi:10.1002/med.21437
   PubMed Web of Science ®Google Scholar
• Wanczyk M, Roszczenko K, Marcinkiewicz K, Bojarczuk K, Kowara M, Winiarska M. HDACi–going through the mechanisms. Front Biosci. 2011;16(1):340–359. doi:10.2741/3691
   Web of Science ®Google Scholar
• Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019–1028. doi:10.1038/leu.2008.397
   PubMed Web of Science ®Google Scholar
• Gore SD. New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2011;2011(1):550–555. doi:10.1182/asheducation-2011.1.550
   Web of Science ®Google Scholar
• Hekmatimoghaddam S, Zare-Khormizi MR, Pourrajab F. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases. Biofactors. 2017;43(6):737–759. doi:10.1002/biof.1264
   Web of Science ®Google Scholar
• Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20(3):3898–3941. doi:10.3390/molecules20033898
   PubMed Web of Science ®Google Scholar
• Prada-Arismendy J, Arroyave JC, Röthlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63–76. doi:10.1016/j.blre.2016.08.005
   PubMed Web of Science ®Google Scholar
• Zaidi SZ, Owaidah T, Al Sharif F, Ahmed SY, Chaudhri N, Aljurf M. The challenge of risk stratification in acute myeloid leukemia with normal karyotype. Hematol Oncol Stem Cell Ther. 2008;1(3):141–158. doi:10.1016/S1658-3876(08)50023-9
   Google Scholar
• Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92. doi:10.3389/fonc.2018.00092
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271–3279. doi:10.1182/blood-2006-03-009142
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibitors in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12):6361–6369. doi:10.1158/0008-5472.CAN-06-0080
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Gemtuzumab ozogamicin: FDA-Approved Drugs. Retrieved from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060.
   Google Scholar
• European Medicines Agency. Mylotarg EPAR. Retrieved from: https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0.
   Google Scholar
• FDA approves venetoclax in combination for AML in adults; 2020. Retrieved from: https://www.fda.gov/drugs/fda-approves-venetoclax-combination-aml-adults.
   Google Scholar